Last reviewed · How we verify
Dihydroartemisinin piperaquin
Dihydroartemisinin piperaquine is a fixed-dose combination antimalarial that kills malaria parasites through artemisinin-induced oxidative stress and piperaquine-mediated heme polymerization inhibition.
Dihydroartemisinin piperaquine is a fixed-dose combination antimalarial that kills malaria parasites through artemisinin-induced oxidative stress and piperaquine-mediated heme polymerization inhibition. Used for Uncomplicated malaria caused by Plasmodium falciparum, Malaria caused by Plasmodium vivax.
At a glance
| Generic name | Dihydroartemisinin piperaquin |
|---|---|
| Also known as | DHAPQ |
| Sponsor | University Clinical Research Center, Mali |
| Drug class | Artemisinin-based combination therapy (ACT) |
| Target | Plasmodium falciparum heme detoxification pathway; artemisinin-derived free radicals |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Dihydroartemisinin (DHA), the active metabolite of artemisinin, generates reactive oxygen species that damage parasite proteins and DNA. Piperaquine is a quinoline-based antimalarial that inhibits heme polymerization, causing toxic heme accumulation in the parasite. Together, this combination provides rapid parasite clearance and extended post-treatment suppression.
Approved indications
- Uncomplicated malaria caused by Plasmodium falciparum
- Malaria caused by Plasmodium vivax
Common side effects
- Headache
- Fever
- Nausea
- Dizziness
- Abdominal pain
Key clinical trials
- Additional Screening With Sensitives RDTs and Malaria (PHASE3)
- Seasonal Malaria Chemoprevention With Dihydroartemisin Piperaquin vs. Sulfadoxine-pyrimethamin+Amodiaquin (PHASE3)
- Evaluation of Three Artemisinin-based Combinations for the Treatment of Uncomplicated Malaria in Childreen in Burkina Faso (CHIMIO2) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: